Aniracetam
Aniracetam
A potent racetam nootropic that enhances memory and cognition while providing anxiolytic effects through unique receptor modulation.
Aniracetam is a fat-soluble racetam nootropic that was developed in the 1970s. It's more potent than piracetam and has a unique profile that includes both cognitive enhancement and anxiolytic (anti-anxiety) effects. It works by modulating AMPA receptors, enhancing cholinergic transmission, and affecting dopamine and serotonin systems. The combination of cognitive and mood benefits makes it popular among nootropic users.
Mechanisms of Action
AMPA Receptor Modulation
Positive modulator of AMPA receptors
Cholinergic Enhancement
Increases acetylcholine activity
Dopamine & Serotonin
Modulates mood neurotransmitters
Recommended Dose
750-1500mg daily in divided doses
Loading: Not required
Optimal Timing
- With fat-containing food (improves absorption)
- Divided into 2-3 doses due to short half-life
- With a choline source
Take with food
Best Form
Aniracetam powder or capsules
Available as powder or capsules. Powder has bitter taste. Take with fatty meal or fish oil.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: 8-12 weeks on, 2-4 weeks off; some use continuously
Note: Fat-soluble; must be taken with food containing fat for proper absorption. Short half-life (1-2 hours) requires multiple daily doses.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Cognitive Enhancement
Improved memory, focus, and verbal fluency
Anxiety Reduction
Reduced social and general anxiety
Creativity Boost
Enhanced creative thinking and idea flow
Short Duration
Effects last only 2-3 hours per dose
May provide dual cognitive and anxiolytic benefits
Who Should NOT Take This
- Severe kidney impairment
Drug Interactions
Synergistic effects with other racetams; adjust doses
Possible Side Effects
Tip: Take with choline source
Tip: Take with food
Tip: Avoid evening doses
Warnings
- Not FDA-approved in US
- Prescription medication in Europe
- Combine with choline to prevent headaches
Top studies from 15+ peer-reviewed papers
Perng CH et al. • Psychopharmacology (2018)
“The most effective intervention for dementia available is symptomatic treatment for vascular dementia.”
Key Findings:
- The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
- The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
- Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment.
- Alternative therapies are also effective at present.
Deutschenbaur L et al. • Progress in neuro-psychopharmacology & biological psychiatry (2016)
“All rights reserved.”
Key Findings:
- Based on glutamatergic signaling, a number of therapeutic drugs might gain interest in the future.
- Drugs targeting the glutamatergic system might open up a promising new territory for the development of drugs to meet the needs of patients with major depression.Copyright © 2015 Elsevier Inc.
- All rights reserved.
Koliaki CC et al. • CNS neuroscience & therapeutics (2012)
“Our findings indicate that aniracetam (a nootropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity.”
Key Findings:
- In patients treated with aniracetam, all studied parameters were adequately maintained at 6 and 12 months, while emotional state was significantly improved at 3 months.
- Our findings indicate that aniracetam (a nootropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity.
- It preserved all neuropsychological parameters for at least 12 months, and seemed to exert a favorable effect on emotional stability of demented patients.
Zhong J et al. • Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
“Shenwu gelatin capsule has certain effects on mild cognitive impairment.”
Key Findings:
- Shenwu gelatin capsule has certain effects on mild cognitive impairment.
- Published in Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
- Further research warranted to confirm findings
O'Neill MJ et al. • Current drug targets (2007)
“The present review summarises studies into the effects of AMPA receptor potentiators (with a focus on the biarylpropylsulfonamides) in rodent models of depression and Parkinson's disease.”
Key Findings:
- In recent years several classes of AMPA receptor potentiators have been reported in the literature, including pyrrolidones (piracetam, aniracetam), benzothiazides (cyclothiazide), benzylpiperidines (CX-516, CX-546) and biarylpropylsulfonamides (LY392098, LY404187, LY450108, LY451395 and LY503430).
- Clinical and preclinical data have suggested that positive modulation of AMPA receptors may be therapeutically effective in the treatment of cognitive deficits.
- However, recent evidence has shown that in addition to modulating fast synaptic plasticity and memory processes, AMPA receptor potentiators alter downstream signalling pathways and may thereby have utility in other CNS disorders.
- The present review summarises studies into the effects of AMPA receptor potentiators (with a focus on the biarylpropylsulfonamides) in rodent models of depression and Parkinson's disease.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.